POLICY NAME Egrifta SV (tesamorelin acetate) POLICY # 1943P

## Criteria

Coverage Criteria	
	Diagnosis of human immunodeficiency virus (HIV)
	Documented presence of abdominal lipodystrophy (abnormal fat distribution)
	Documentation which indicates the sole purpose of treatment is not weight loss
	Documented compliance with antiretroviral therapy (ART; such as Biktarvy, Complera, etc)
Approval Criteria	
	Initial: 12 months
	Renewal: 12 months with demonstrated a clear clinical improvement from baseline that is supported by a waist circumference or CT scan CPT Codes HCPCS Codes